We are live on
!
Find out more
GFM
GF Fund Management Portfolio holdings
AUM
$5.98B
1-Year Est. Return
80.99%
This Fund
S&P 500
This Quarter
Est. Return
+7.58%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
98.7%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$400M |
| 2 |
Apple
AAPL
|
+$352M |
| 3 |
Microsoft
MSFT
|
+$326M |
| 4 |
Amazon
AMZN
|
+$218M |
| 5 |
Meta Platforms (Facebook)
META
|
+$195M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.41% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRFS
476
Grifois
GRFS
$5.36B
| $19.1K | ﹤0.01% |
+2,562
| New | +$21.4K |
|
477
ArriVent BioPharma
AVBP
$1.39B
| $18.9K | ﹤0.01% |
+708
| New | +$20.3K |
|
478
Adaptive Biotechnologies
ADPT
$3.59B
| $18.6K | ﹤0.01% |
+3,099
| New | +$17.1K |
|
479
Genmab
GMAB
$17.7B
| $18.4K | ﹤0.01% |
+880
| New | +$19.3K |
|
480
Pacira BioSciences
PCRX
$1.04B
| $18.3K | ﹤0.01% |
+970
| New | +$17K |
|
|
CSR
481
Centerspace
CSR
$921M
| $18.3K | ﹤0.01% |
+276
| New | +$19.4K |
|
482
AbCellera Biologics
ABCL
$1.74B
| $18.2K | ﹤0.01% |
+6,202
| New | +$17.3K |
|
483
Cogent Biosciences
COGT
$6.65B
| $18.1K | ﹤0.01% |
+2,319
| New | +$23.1K |
|
484
uniQure
QURE
$3.03B
| $18.1K | ﹤0.01% |
+1,023
| New | +$8.83K |
|
485
Kiniksa Pharmaceuticals
KNSA
$5.8B
| $17.3K | ﹤0.01% |
+873
| New | +$19.9K |
|
|
NXRT
486
NexPoint Residential Trust
NXRT
$666M
| $17.2K | ﹤0.01% |
+412
| New | +$18.2K |
|
487
Pliant Therapeutics
PLRX
$64.4M
| $16.8K | ﹤0.01% |
+1,278
| New | +$17.4K |
|
|
LENZ
488
LENZ Therapeutics
LENZ
$166M
| $16.7K | ﹤0.01% |
+577
| New | +$17.6K |
|
489
Vistra
VST
$50B
| $16.5K | ﹤0.01% |
+120
| New | +$16.7K |
|
490
Maravai LifeSciences
MRVI
$969M
| $16.2K | ﹤0.01% |
+2,978
| New | +$19.2K |
|
|
CVAC
491
DELISTED
CureVac
CVAC
| $16.1K | ﹤0.01% |
+4,710
| New | +$13.6K |
|
492
Castle Biosciences
CSTL
$855M
| $15.7K | ﹤0.01% |
+588
| New | +$17.9K |
|
493
Prothena Corp
PRTA
$425M
| $15.7K | ﹤0.01% |
+1,130
| New | +$17.8K |
|
|
PGRE
494
DELISTED
Paramount Group
PGRE
| $15.5K | ﹤0.01% |
+3,137
| New | +$15.5K |
|
|
SAFE
495
Safehold
SAFE
$1.16B
| $15.5K | ﹤0.01% |
+837
| New | +$18.2K |
|
496
Erasca
ERAS
$6.3B
| $14.9K | ﹤0.01% |
+5,936
| New | +$16.3K |
|
497
Cullinan Oncology
CGEM
$1.01B
| $14.9K | ﹤0.01% |
+1,223
| New | +$17.6K |
|
498
Ironwood Pharmaceuticals
IRWD
$696M
| $14.9K | ﹤0.01% |
+3,360
| New | +$13.6K |
|
499
Tyra Biosciences
TYRA
$1.9B
| $14.8K | ﹤0.01% |
+1,063
| New | +$19.3K |
|
|
AHRT
500
AH Realty Trust
AHRT
$529M
| $14.7K | ﹤0.01% |
+1,437
| New | +$15.6K |
|
Similar funds
CM
BP
AAM
CAG
RCG
AL
CGPCS
EAM
GF Fund Management's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for GF Fund Management, which disclosed 637 positions worth $4.62B. Its ten largest holdings account for 48% of the portfolio.
Its largest position is NVIDIA: 2,904,119 shares worth $390M.
By sector, the portfolio is most concentrated in Technology at 45% of assets, followed by Consumer Discretionary and Communication Services.
- GF Fund Management's largest Q4 2024 buy was NVIDIA: 2,904,119 shares worth $390M.
- GF Fund Management's ten largest holdings make up 48% of its $4.62B portfolio in Q4 2024.
- GF Fund Management disclosed 637 positions in Q4 2024, its first 13F filing on record.
Based on GF Fund Management's 13F filing for Q4 2024, filed 19 Feb 2025.